You are here: Welcome to the MPKB » Welcome to the MPKB » Science behind Marshall Paradigm » Science behind Marshall Protocol antibiotics
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:protocol:mp_antibiotics [01.09.2013] – [Mechanisms of action] sallieqhome:protocol:mp_antibiotics [01.08.2014] – [Mechanisms of action] sallieq
Line 2: Line 2:
 ====== Science behind Marshall Protocol antibiotics     ====== ====== Science behind Marshall Protocol antibiotics     ======
  
-The Marshall Protocol (MP) employs rotating combinations of subinhibitory bacteriostatic antibiotics at pulsed doses for maximum effectiveness. The type of bacterial pathogens the MP targets are chronic forms, bacteria that grow much more slowly than acute forms. +NOTE: Antibotics are no longer a compulsory part of the Marshall protocol.  
 + 
  
 ===== Safety of Marshall Protocol antibiotics  ===== ===== Safety of Marshall Protocol antibiotics  =====
Line 33: Line 35:
 Emerging research now suggests that antibiotics have much broader range of actions that once supposed. Emerging research now suggests that antibiotics have much broader range of actions that once supposed.
  
-N.B. azithromycin is no longer recommended for use while on the MP 
  
 ^Name   ^Action(s) ^ ^Name   ^Action(s) ^
 |Minocycline    |interferes with bacterial protein synthesis by binding to the 30S subunit of the bacterial ribosome; may bind the PXR Nuclear Receptor; inhibits activity of caspase-3    |   |Minocycline    |interferes with bacterial protein synthesis by binding to the 30S subunit of the bacterial ribosome; may bind the PXR Nuclear Receptor; inhibits activity of caspase-3    |  
-|Azithromycin (Zithromax)     |interferes with bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome;  significantly inhibited expression of co-stimulatory molecules (CD40 and CD86) and major histocompatibility complex (MHC) class II by dendritic cells; reduces toll-like receptor 4 expression, interleukin-12 production and the allostimulatory capacity of dendritic cells(({{pubmed>long:22059997}})) |+|Azithromycin (Zithromax) //no longer recommended//     |interferes with bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome;  significantly inhibited expression of co-stimulatory molecules (CD40 and CD86) and major histocompatibility complex (MHC) class II by dendritic cells; reduces toll-like receptor 4 expression, interleukin-12 production and the allostimulatory capacity of dendritic cells(({{pubmed>long:22059997}})) |
 |Clindamycin   |interferes with bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome     | |Clindamycin   |interferes with bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome     |
 |Demeclocycline (Declomycin)  |interferes with bacterial protein synthesis by binding to the 30S and 50S subunit of the bacterial ribosome     |        |Demeclocycline (Declomycin)  |interferes with bacterial protein synthesis by binding to the 30S and 50S subunit of the bacterial ribosome     |       
home/protocol/mp_antibiotics.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.